1   New mechanism of fibronectin fibril assembly revealed by live imaging and super-resolution
2   microscopy.
3
4

5   Darshika Tomer[1], Sudipto Munshi[2], Brianna E. Alexander[1,3], Brenda French[2], Pavan Vedula[4],
6   Andrew House[5], Murat Guvendiren[5], Anna Kashina[4], Jean E. Schwarzbauer[6], and Sophie
7   Astrof[1,*].
8
9

10 1.   Department of Cell Biology and Molecular Medicine, Cardiovascular Research Institute,
11   Rutgers Biomedical and Health Sciences, 185 South Orange Ave, Newark, NJ, 07103,
12   USA.
13
14 2.   Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA,
15   19107, USA
16
17 3.   Multidisciplinary PhD Program in Biomedical Sciences. Cell Biology, Neuroscience and
18   Physiology track, Rutgers Biomedical and Health Sciences, Newark, NJ, 07103, USA.
19
20 4.   Department of Biomedical Sciences, University of Pennsylvania, Philadelphia, PA
21   19104, USA
22
23   5.   Otto H. York Chemical and Materials Engineering, Department of Biomedical
24   Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA
25
26 6.   Department of Molecular Biology, Princeton University, Princeton, New Jersey, USA
27
28
29
30 *Author for correspondence: Sophie Astrof, Ph.D.
31 Phone: 617-429-8295
32 E-mail: sophie.astrof@rutgers.edu

Abstract

Fibronectin (Fn1) is an essential ECM glycoprotein important for embryonic development and homeostasis. The functions of Fn1 in regulating cell fate decisions, morphogenesis and cellular responses to injury are intimately linked to the process of Fn1 fibrillogenesis. Therefore, understanding the mechanisms by which Fn1 proteins assemble into fibrils is necessary to gain insights into diverse functions of Fn1. Using CRISPR/Cas9 mutagenesis, we generated mice and cell lines wherein a sequence encoding a fluorescent protein (FP) was knocked into the *Fn1* locus replacing the termination codon, resulting in the expression of Fn1-FP proteins subject to endogenous regulation. Live imaging and super-resolution microscopy revealed that Fn1 fibrils are not continuous fibers as was thought before, instead, they are comprised of a discontinuous array of small nanodomains. Live imaging showed that Fn1 nanodomains are mobile and that they become arranged into progressively longer linear arrays as they move toward the nucleus in parallel with the rearward actin flow. The organization of Fn1 nanodomains into linear fibrillar arrays but not the formation of Fn1 nanodomains is regulated by the interactions mediated by the Fn1 N-terminal assembly domain. The nanodomain architecture of Fn1 fibrils is observed in multiple contexts: in three-dimensional ECM *in vivo*, on substrata of different composition and stiffness, and is retained when the linkage of Fn1 fibrils to cells is disrupted. The modular assembly and structure of Fn1 fibrils bears important implications for mechanisms of ECM remodeling and signal transduction.

Introduction

Fibronectin (Fn1) is a requisite component of extracellular matrix (ECM) necessary for

embryogenesis and homeostasis (Schwarzbauer and DeSimone, 2011). It is noteworthy that in

the absence of Fn1 fibrillogenesis, the binding of Fn1 to cells is not sufficient to regulate key

biological processes including those governing embryonic development, angiogenesis,

vascular remodeling, or cartilage condensation (Chiang et al., 2009; Rozario et al., 2009;

Singh and Schwarzbauer, 2014; Zhou et al., 2008). Therefore, understanding the mechanisms

by which Fn1 proteins assemble into macromolecular fibrils is essential to gain insights into *in*

vivo functions of Fn1. Fn1 fibrillogenesis occurs following the binding of secreted Fn1

homodimers to cell-surface integrins. Following integrin binding, intracellular cytoskeletal

forces such as actomyosin contractility acting through integrins generate pulling forces on Fn1

dimers, exposing epitopes that promote Fn1 fibrillogenesis (Chernousov et al., 1987; Smith et

al., 2007; Zhang et al., 1994; Zhang et al., 1997; Zhong et al., 1998). At the cell biological

level, the process of Fn1 fibrillogenesis is correlated with the formation of fibrillar adhesions,

whereby mobile adhesions containing Fn1 and integrin $\alpha 5\beta 1$ translocate toward the nucleus

resulting in elongated linear arrays termed focal and fibrillar adhesions, containing both Fn1

and intracellular cytoplasmic effectors linking Fn1 and actin cytoskeleton (Geiger et al., 2001;

Geiger and Yamada, 2011; Lu et al., 2020; Pankov et al., 2000; Zamir et al., 1999; Zamir et al.,

2000).

It has been thought that Fn1 fibrils arise following partial unfolding and alignment of Fn1

dimers in a periodic end-to-end fashion of alternating N- and C-termini, forming continuous

fibers (Chen et al., 1997; Dzamba and Peters, 1991; Fruh et al., 2015). However, this model is

based on the analyses of fixed samples and electron microscopy wherein the exact

composition of the fibrous material imaged could not be easily determined. To evaluate the

process of fibrillogenesis in real time, we adopted a CRISPR/Cas9-mediated mutagenesis

approach to generate fluorescently-labeled Fn1, subject to physiological regulation of

expression and splicing. This approach has enabled us to visualize the initiation and

progression of Fn1 fibrillogenesis over an extended period of time. Using live imaging and

super resolution microscopy, we uncovered an unexpected mechanism of Fn1 fibrillogenesis.

Our data demonstrate that Fn1 fibrils are composed of centripetally-moving Fn1 nanodomains

originating at cell periphery. As Fn1 nanodomains move toward the nucleus, they become

arranged into progressively longer and longer arrays wherein nanodomains containing a high

number of Fn1 dimers alternate with regions containing low or no Fn1. We show that the N-

terminal Fn1 assembly region is not required for the formation of Fn1 nanodomains or their

centripetal translocation. Instead, the N-terminus of Fn1 regulates the organization of Fn1

nanodomains into linear arrays. This model of fibrillogenesis integrates the process of

fibrillogenesis with adhesion maturation and provides significant new insights into the

mechanisms of ECM formation,

remodeling, and signaling.

Results

While examining Fn1$^+$ ECM by

confocal immunofluorescence microscopy

in mouse embryos, we observed that Fn1

fibrils appeared discontinuous (**Fig. 1a-b**,

arrows), containing regularly-spaced

regions of high and low fluorescence

intensity (**Fig. 1c, Movie 1**; *Movie legends*

are at the end of the manuscript). This

suggested that Fn1 fibrils consisted of

regions with a high number of Fn1 dimers

Figure 1. Beaded architecture of Fn1 fibrils in embryonic ECM. Wild-type E9.5 mouse embryos were fixed and stained with the monoclonal antibody to Fn1 (white) and DAPI, and imaged using 100x oil objective, N.A. 1.49, pinhole 0.8, and sampling rate of 40 nm/pixel. **a – a1.** Sagittal optical section through the first pharyngeal arch and **b.** the cardiac jelly, an ECM-rich region between the myocardial and endocardial layers of the outflow tract of the heart. Large arrowheads in **a – a1** point to the ECM at the ectoderm-mesenchyme boundary of the 1st pharyngeal arch. The box in **(a)** is expanded in **a1** to show the beaded Fn1 microarchitecture. Arrow in **a1** points to Fn1 fibril within the arch mesenchyme; **b.** Beaded architecture of Fn1 fibrils in cardiac jelly, e.g., arrow. **c.** Intensity profile plot of a Fn1 fibril shows a regularly-undulating profile, with peaks corresponding with Fn1 "beads"; a.u. arbitrary units.

separated by regions containing a low number of Fn1 dimers (**Fig. 1c**). To test this hypothesis

and to determine mechanisms regulating the formation of Fn1 fibrils, we employed a

CRISPR/Cas9 knock-in strategy to modify the endogenous Fn1 locus by replacing the

termination codon of Fn1 with a sequence encoding a fluorescent protein. This strategy has

allowed to generate fluorescently-labeled Fn1 proteins subject to endogenous regulation (**Sup.**

Fig. 1a-b), and enabled extended live imaging of Fn1 fibrillogenesis. Using this strategy, we

obtained multiple independent lines of mouse embryo fibroblasts (MEFs) expressing Fn1-

mEGFP, Fn1-mScarlet-I, Fn1-Neon Green, or Fn1-tdTomato fusion proteins (FP) generated by

CRISPR/Cas9-mediated insertion. Western blots showed that FP fusions to Fn1 were specific:

FPs were only fused to Fn1 as no other FP fusions were detected either by western blotting or

immunofluorescence (IF) (**Sup. Fig. 2a-b**).

Deoxycholate (DOC) insolubility of Fn1 ECM is a classical biochemical assay for

proteins stably incorporated into the assembled ECM (Choi and Hynes, 1979; McKeown-

Longo and Mosher, 1983; Singh et al., 2010; Wierzbicka-Patynowski et al., 2004). DOC

assays demonstrated that the incorporation of Fn1-FPs into ECM was indistinguishable from

wild-type, untagged Fn1 (**Sup. Fig. 2c**). To determine whether Fn1-FP proteins carried out the

physiological functions of Fn1, we generated Fn1^{mEGFP} knock-in mice. Fn1$^{mEGFP/mEGFP}$

homozygous knock-in animals are viable and fertile (**Sup. Fig. 1b** panels 4 and 5).

Furthermore, Fn1-mEGFP proteins were expressed in the same pattern as total Fn1 protein

(**Sup. Fig. 2d**) (Peters and Hynes, 1996). Together, these studies demonstrated that Fn1-FP

fusion proteins are suitable reagents for investigating mechanisms of Fn1 fibrillogenesis.

To visualize the process of fibrillogenesis in real time, we plated Fn1$^{mEGFP/+}$ MEFs on

gelatin-coated cover glass and imaged cells 16 hours after plating using total internal reflection

(TIRF) microscopy at the critical angle of incidence. These experiments showed that Fn1

fibrillogenesis initiated at cell periphery as distinct bright Fn1 densities that moved centripetally

in parallel with F-actin and aligned into linear arrays of "beads" (arrows in **Movie 2**). TIRF

Figure 2. Integrin α5β1 and Fn1 co-localize in beaded adhesions. Wild-type MEFs were plated for 16 hours on glass coverslips, then fixed, stained with antibodies to Fn1 and integrin α5 (Itga5), and imaged at the critical angle of incidence using 100x oil objective, NA 1.49. **a – a2** cell periphery. Arrows in **a-a2** point to examples of non-fibrillar Fn1 adhesions ("beads") at cell periphery. **b - b2** medial portion of a cell containing beaded fibrillar adhesions (arrows). Note that both Itga5 and Fn1 stainings are beaded. Magnifications in all panels are the same.

imaging also showed that the domains of higher fluorescence intensity of Fn1 co-localized with

integrin α5β1 both in non-fibrillar adhesions (arrows in **Fig. 2a-a2**) and in fibrillar adhesions

(arrows in **Fig. 2b-b2**), and that Fn1 and α5β1 fibrillar adhesions are beaded (**Fig. 2b-b2**,

arrows). We also observed the beaded architecture of Fn1 fibrils using an independent

imaging method by employing Zeiss Airyscan (**Sup. Fig. 3**). Staining using monoclonal and

polyclonal antibodies recognizing distinct and multiple epitopes in Fn1 resulted in the

discontinuous appearance of Fn1 fibrils (**Fig. 3a1-c1**). Fn1 fibrils formed by cells plated on

glass, gelatin, laminin 111 or vitronectin were beaded Fn1 fibrils (**Fig. 3**, and **Sup. Figs. 3-4**),

and so were Fn1 fibrils in cell-free areas (**Fig. 3a, a1**) and between cells (**Fig. 3b-c**). In

addition, the beaded appearance of Fn1 fibrils was observed when cells were plated on soft

substrata such as hydrogels of variable stiffness (**Sup. Fig. 4c-d**). In the latter experiment, Fn1

was detected by imaging the native fluorescence of Fn1-mEGFP, indicating that the beaded

appearance of Fn1 fibrils was

independent of antibody

staining. Taken together, these

studies indicated that the

beaded appearance of Fn1

fibrils was a general feature of

Fn1 ECM seen in 3D ECM *in*

vivo and under different

conditions *in vitro*.

To test the hypothesis

that the "beads" in Fn1 strings

were contiguous, cultures were

treated with 2% DOC. 2% DOC

treatment dissolves cell

membranes and cytoplasmic

components, leaving insoluble

ECM devoid of cell contact (see

Movie 3 for time-laps of

dissolution of cellular

components, F-actin and DNA).

This experiment showed that

Figure 3. Beaded architecture of Fn1 fibrils is present in fibrils between cells and is retained in the absence of cell contact. a-b. Fn1 secreted by wild-type MEFs and deposited **a)** on glass or **b)** between cells. **c.** Fn1 fibrils between endothelial cells. Boxes in **a – c** are magnified in **a1-c1.** Arrows point to fibrils left behind on substrata (**a1**) or between cells (**b1-c1**). **d.** Fn1^Neon Green MEFs were treated with 2% DOC pH 8 until cells were dissolved (see Movie 3). Following DOC treatment, Fn1 was imaged using 100x oil objective, NA 1.49, pinhole size 0.8 Airy units, and sampling resolution of 40 nm/pixel in x,y. Note beaded architecture (arrows).

Fn1 fibrils in assembled ECM retained their beaded architecture in the absence of cell contact

(**Fig. 3d**). Together, these data indicated that the beaded topology of Fn1 fibrils is a feature of

physiological three-dimensional Fn1 ECM *in vivo* and suggested that the beads are

contiguous.

To determine the relationship between the beaded architecture of Fn1 seen by

diffraction-limited microscopy with Fn1 nanoarchitecture, we plated Fn1$^{mEGFP/+}$ MEFs on glass

for 16 hours, then fixed and stained cells using a monoclonal antibody to the central region of

Fn1. Fn1-mEGFP fluorescence was imaged in the TIRF mode at the critical angle of incidence,

while the binding of the monoclonal αFn1 antibody was detected with Alexa Fluor-647-

conjugated secondary antibody and imaged by Stochastic Optical Reconstruction Microscopy

(STORM). STORM was performed by illuminating samples at the critical angle of incidence, as

described in (Jimenez et al., 2020). Thin beaded fibrillar adhesions (arrow in **Fig. 4a**) were

resolved by STORM (**Fig. 4b-b2**) to be arrays of regularly-spaced nanodomains that were

Figure 4. Fn1 fibrils are composed linear arrays of Fn1 nanodomains. Fn1$^{mEGFP/+}$ MEFs were plated on glass for 16 hrs, then fixed and stained with antibodies to GFP followed by secondary antibodies conjugated to Alexa-647. **a.** Native GFP fluorescence imaged by TIRF using 100x objective NA 1.49. Arrow in **a** points to a thin, beaded Fn1 fibril resolved by STORM in **b1, b1'** and **b2. b.** The entire field of view in **a** is imaged by STORM detecting Alexa-Fluor 647-conjugated antibody (see Methods). The box in **b** is expanded in **b1**. The box in **b1** is expanded in **b2**. The arrow in **b1** points to the same region as the arrow in **a**. Arrows in **b2** point to Fn1 nanodomains; arrowheads point to Fn1 localizations between the nanodomains, notched arrowheads point to Fn1 nanodomains that are not in fibrils and wide arrows point to Fn1-free areas between the nanodomains in the fibril marked by the arrow in **a. a, b, b1, b1'** and **b2** are in x-y planes; **b2'** shows the nanodomains in **b2** in the x-z plane. Images in **b1'** and **b2'** are depth-coded according to the scale in **b1'**. See Movie 4 for 3D rotation of the fibril underlined in **b1'** around the x-axis.

symmetrical in x, y, and z dimensions (**Fig. 4b1, b2, b2'** and **Movie 4**). The space between

nanodomains contained a few or no Fn1 localizations (**Fig. 4b2** and **Movie 4**).

Fn1 is a large, multi-domain, ~250 kDa glycoprotein secreted as a homodimer, wherein

Fn1 subunits are linked in the anti-parallel orientation by two di-sulfide bonds at their C-termini

(Schwarzbauer and DeSimone, 2011; Skorstengaard et al., 1986). To investigate the

relationship between the domain structure of Fn1 protein and the nanodomain architecture of

Fn1 fibrils, we used antibodies to distinct parts of Fn1 protein (depicted in **Model 1** at the

bottom of **Fig. 5**,) and STORM. For these experiments, wild-type and $Fn1^{mEGFP/+}$ MEFs were

sparsely-plated in Ibidi 8-well glass-bottom chambers overnight, allowing to observe the

structure of thin fibrils. Cells were then fixed and stained with antibodies recognizing different

Fn1 epitopes: polyclonal rabbit antibodies raised to recognize the first six type III repeats of

Fn1 (Fn1 III_{1-6}) (Vega et al., 2020) (**Fig. 5** column 1), a monoclonal antibody recognizing an

epitope within the central region of Fn1 (**Fig. 5** columns 2, 4-5), polyclonal anti-serum 297.1

raised against the entire Fn1 protein (Rickelt and Hynes, 2018) (**Fig. 5**, column 3), or

polyclonal antibodies to GFP, recognizing the C-terminus of Fn1-mEGFP protein (**Fig. 6**,

column 5). To maximize the labeling density, the polyclonal anti-Fn1 III_{1-6} and 297.1 antisera

were used at a 40- and 4-fold higher concentrations than for routine immunofluorescence

microscopy, respectively. Together with the use of excess secondary antibodies each

conjugated to 3 – 6 molecules of Alexa-647, this approach maximizes the chance that all the

epitopes recognized by the 1° antibodies will be localized by STORM (Jimenez et al., 2020).

We first focused on the analyses of thin Fn1 fibrils like those marked by the arrows in

(**Fig. 4a-b**) to study the initiation of fibril formation rather than fibril bundling or branching. Each

antibody resulted in the detection of long characteristic Fn1 fibrils (**Fig. 5a-c**). Successive

magnifications show that independent of the antibody used for staining, Fn1 fibrils contained

linear arrays of nanodomains (thin arrows in **Fig. 5d, magnified in 5e**) separated by regions

containing a small number or no Fn1 localizations (as in **Fig. 4, Movie 4**).

Figure 5. Fn1 fibrils are composed of nanodomains containing multiple Fn1 dimers. Wild-type or Fn1mEGFP/+ MEFs were plated on glass for 16 hrs, fixed and stained with different antibodies to Fn1 followed by Alexa 647-conjugated secondary antibodies. Columns showing cells treated with DOC prior to fixation are marked. Cells were imaged using STORM. **a.** zoom-out views to show the overall appearance of Fn1 fibrils. **b-e.** Successive magnifications of fibrils shown in (**a**). Arrows in **d** point to nanodomains magnified in **e;** arrowheads in **d-e** point to Fn1 molecules between nanodomains, wide open arrows point to Fn1-free zones between nanodomains in a fibril. **f.** distances between nanodomains within fibrils or non-fibrillar (NF) nanodomains, **** $p<10^{-4}$, Kruskal-Wallis test, with Dunn's correction for multiple testing. Inset in **f** is a plot profile of the fibril marked by the box in the column **6d** showing regularly-spaced peaks of intensity. DOC-treated samples are marked. 4-antibody cocktail contains four antibodies as in **Model 1**. **g.** Diameter of nanodomains in fibrils. **h.** number of Fn1 localizations per nanodomain in fibrils. **Model 1**. Two Fn1 dimers in a fibril. Depiction of antibody coverage of Fn1 fibrils if dimers were oriented in end-to-end fashion with alternating N- and C-termini. **Model 2.** Our data show that Fn1 fibrils consist of a linear array of nanodomains (black arrows) containing multiple Fn1 dimers (Fn1 dimers are depicted as balls and color-coded according to the antibody scheme in **Model 1**. Arrowheads point to Fn1 and open arrows point to Fn1-free areas between nanodomains.

Surprisingly, staining with the polyclonal anti-serum 297.1 raised to the entire Fn1 and,

presumably, recognizing multiple epitopes along Fn1, resulted in the same pattern of regularly-

spaced nanodomains as staining with antibodies recognizing distinct parts of Fn1 molecule

(**Fig. 5,** column 3), suggesting that each Fn1 localization contained the entire Fn1 sequence,

and that each nanodomain contained multiple Fn1 dimers.

These data are not consistent with previous models suggesting that Fn1 fibrils are composed

of periodically aligned Fn1 dimers arranged in an end-to-end fashion of alternating N- and C-

termini (Chen et al., 1997; Dzamba and Peters, 1991; Fruh et al., 2015) (**Model 1** at the

bottom of **Fig. 5**). Such periodic alignment of Fn1 dimers necessitates that staining using

polyclonal antibodies would result in a uniform labeling of thin Fn1 fibrils, as depicted in **Model**

1. The dimers in the **Model 1** are aligned in an end-to-end fashion, according to the current

Fn1 fibrillogenesis model, with the predicted overlap between the N-terminal Fn1 assembly

domain (blue) and the first six type III repeats of Fn1 (red) (Singh et al., 2010)). If Fn1 fibrils,

were indeed composed of continuous, linear arrays of dimers, the use of all four depicted in

Model 1 would be predicted to uniformly label Fn1 fibrils.

To test this prediction, we used Fn1$^{mEGFP/+}$ MEFs and a cocktail of four antibodies recognizing

the beginning (αFn1 III$_{1-6}$), middle- (αFn1 monoclonal), and the end (αGFP) of Fn1-mEGFP

protein in addition to all the epitopes recognized by 297.1 polyclonal antibody. The binding of

all the antibodies in the cocktail was detected by a cocktail of secondary antibodies that were

each conjugated to 3 – 6 molecules of Alexa-647 (**Fig. 5, column 7**). The nanoarchitecture of

thin Fn1 fibrils, the nanodomain spacing (124 $\pm$ 25 nm between nanodomains in fibrils, on

average), nanodomain size (average diameter 77 $\pm$ 18 nm), and the number of Fn1

localizations per nanodomain (average of 80 $\pm$ 43 localizations) detected by the cocktail of four

antibodies were indistinguishable from those produced by each type of the antibody

individually (**Fig. 5d – e**, quantified in **Fig. 5f-h** and **Tables 1 –3**). These results indicate that

Fn1 fibrils are not uniform. Instead, our data show that Fn1 fibrils are arrays of nanodomains

containing multiple Fn1 dimers separated by areas containing a few or no Fn1 molecules (**Fig.**

5, Model 2). The nanoarchitecture of Fn1 fibrils following the treatment with 2% DOC which

removes cells and cellular components, was similar to untreated fibrils (**Fig. 5,** columns 4 and

8, **Fig. 5f – h**). These data indicate that the nanodomain architecture is a feature of mature

Fn1 fibrils.

Fn1 nanodomains were also present outside of fibrils, we term them non-fibrillar nanodomains

(e.g. notched arrowheads in **Fig. 4**). About 3 – 5 such nanodomains are seen as a "bead" in

conventional diffraction-limited microscopy. Non-fibrillar Fn1 nanodomains contained a similar

number of Fn1 localizations per nanodomain and were of similar size compared with Fn1

nanodomains in fibrils (**Fig. 5h, Tables 2 – 3**). Staining using antibodies to endosomal and

lysosomal markers (Rab5 and LAMP1) showed no appreciable co-localization with Fn1

nanodomains (data not shown). Together with imaging using TIRF microscopy, these findings

indicated that Fn1 nanodomains in fibrils and non-fibrillar nanodomains are on the cell surface.

Non-fibrillar Fn1 nanodomains were present at cell periphery and throughout the cell surface,

but they were not organized into linear arrays and were spaced at an median distance of 329

nm (**Table 1**).

Live imaging experiments suggested that Fn1 fibrils form from centripetally-translocating

Fn1 nanodomains originating at cell periphery (**Movie 2**). To understand the relationship

between the observed nanodomain architecture of Fn1 fibrils and the process of fibrillogenesis,

we adopted a live imaging approach using Fn1$^{mEGFP/+}$ MEFs and inhibitors of fibrillogenesis.

Fn1 fibrillogenesis critically depends on the interactions mediated by the N-terminal assembly

domain of Fn1 (domains shaded in blue in **Model 1, Fig. 5**), and inhibitors that interfere with

these interactions block the formation of Fn1 fibrils (Filla et al., 2017; Morla et al., 1994;

Schwarzbauer, 1991; Sechler et al., 2001; Sechler et al., 1996; Tomasini-Johansson et al.,

2001). One such inhibitor is a 49-amino acid peptide derived from *Streptococcus pyogenes*

adhesin F1, termed the functional upstream domain (FUD) (Tomasini-Johansson et al., 2001).

FUD binds the N-terminal assembly domain of Fn1 and functions as a competitive inhibitor of

Fn1-Fn1 interactions (Maurer et al., 2010; Tomasini-Johansson et al., 2001). To determine

how N-terminal interactions regulate Fn1 fibrillogenesis, $Fn1^{mEGFP/+}$ MEFs were plated on glass

for 4 hours, and then imaged for 15 – 18 hours either in the imaging medium alone, or in the

medium containing either 225 nM FUD or 274 nM 11-IIIC, a 68 amino-acid control peptide that

does not interfere with Fn1 fibrillogenesis (Morla et al., 1994; Sottile and Chandler, 2005).

Untreated cells or cells treated with the control peptide developed and accumulated long Fn1

fibrils (**Movie 5**). In contrast, treatment with FUD led to dismantling of the pre-existing Fn1

fibrils and inhibited the formation of new Fn1 fibrils (**Movie 6**). Instead of fibrils, cells cultured in

the presence of FUD mainly contained centripetally-moving Fn1-mEGFP fluorescent "beads"

that only rarely formed strings (**Movie 6**). These experiments suggested that FUD inhibits

fibrillogenesis by interfering with the process by which Fn1 "beads" become arranged or

connected into linear arrays. To test this hypothesis, $Fn1^{mEGFP/+}$ MEFs were plated for 16 hours

in the continuous presence of either 225 nM FUD or 274 nM III-11C control peptides, or were

left untreated. Cell were then fixed and stained without permeabilization using monoclonal anti-

Fn1 antibodies which were detected with Alexa Fluor 647-conjugated secondary antibodies,

and imaged at the critical angle of incidence by STORM at the excitation wavelength of 640

nm (Jimenez et al., 2020). This approach abolishes the detection of intracellular Fn1-mEGFP

and maximizes the detection of cell-surface Fn1 due to the following: a) the absence of a

detergent during fixation, staining and washing, b) detecting the emission of Alexa 647-

conjugated antibodies at $\geq$ 670 nm, c) the use of oxygen scavengers in the STORM buffer that

inhibits GFP fluorescence (Tsien, 1998), and d) imaging at the critical angle of incidence to

detect fluorescence

in close proximity to

the plasma

membrane. These

experiments

demonstrated that

the organization of

nanodomains into

linear arrays was

lost upon incubation

with FUD (compare

Fig. 6a, b, a1, b1

with **Fig. 6c, c1**).

Non-fibrillar Fn1

nanodomains in

cells treated with

FUD had a similar

number of Fn1

localizations per

nanodomain, and

Figure 6. The N-terminal Fn1 assembly domain regulates the organization of Fn1 nanodomains into linear fibrillar arrays. Fn1$^{mEGFP/+}$ MEFs were plated on glass and were either left untreated, or were incubated with the control 11-IIIC peptide, or the FUD peptide for 16 hrs. Cell were then fixed and stained with the monoclonal antibody to Fn1 followed by Alexa 647-conjugated secondary antibodies. Cells were imaged at the critical angle of incidence by STORM. **a – a2**. Untreated, unpermeabilized cells. **b – b2.** Cells incubated with controls 11-IIIC peptide. **c – c1, c1-1** FUD-treated, unpermeabilized cells. Boxes marked 1 in **a-b** were expanded in **a1-b1**. Boxes marked 2 in **a-b**, were expanded in **a2 – b2**. The box in **c** is expanded in **c1** and **c1-1**. Arrows in **a1-b1** point to Fn1 nanodomains (NDs) in fibrils. Arrows in **c1** points to non-fibrillar nanodomains expanded in c1-1; **d.** Quantification of the number of Fn1 localizations in NDs in fibrils and in non-fibrillar NDs after various conditions. Red lines mark medians. Differences are not statistically significant, Kruskal-Wallis test with Dunn's correction for multiple testing. **e.** Model of fibril formation: Fn1 dimers assemble into small nanodomains containing integrin α5β1 at cell periphery, move rearward with actin flow, and become organized into linear arrays of nanodomains. Joining of the additional Fn1 nanodomains to these arrays leads to the generation of longer fibrils as the assembly moves toward the cell center. FUD does not interfere with the formation of Fn1 nanodomains. But instead, it blocks the organization of Fn1 nanodomains into linear arrays.

were of similar sizes compared with fibrillar or non-fibrillar Fn1 nanodomains in untreated cells

or cells incubated with the control peptide (**Fig. 62-c1-1**, quantified in Fig. **6d** and **Tables 2-3**).

Taken together, these data indicate that FUD does not interfere with the formation of Fn1

nanodomains but inhibits the organization of Fn1 nanodomains into linear arrays. Since Fn1

proteins lacking the N-terminal assembly domain do not form fibrils, our experiments suggest

that interactions mediated by the N-terminal assembly domain of Fn1 are critical for the linking

of Fn1 nanodomains into strings.

Discussion

In this manuscript, we describe the discovery of a novel mechanism underlying the process of

Fn1 fibrillogenesis. We found that the three-dimensional beaded architecture of Fn1 ECM

fibrils *in vivo* and in two-dimensional cell culture is due to the presence of Fn1 nanodomains,

and showed that each Fn1 nanodomain is composed of multiple Fn1 dimers. Time-laps

imaging by confocal and TIRF microscopy showed that Fn1 fibrillogenesis initiated at cell

periphery, as bright fluorescent "beads" of Fn1-mEGFP moved centripetally in parallel with F-

actin and became organized into linear arrays. Interestingly, the beaded appearance of focal

and fibrillar adhesions has been noted before (Zamir et al., 1999; Zamir et al., 2000), and the

beaded architecture of cell adhesions can be seen in micrographs from multiple studies (e.g.

Fig. 1C in (Zamir et al., 1999), Fig 7a and Sup. Figs 1a and b in (Choi et al., 2008); Fig. 8B in

(Damsky et al., 1985); and lower left cell in Fig. 3A (Zhang et al., 2012). However, the

significance of these observations has not been investigated to the best of our knowledge. Fn1

domains and beaded strings in our movies resemble mobile, Fn1[+] adhesions similar to those

described previously (Lu et al., 2020; Pankov et al., 2000; Zamir et al., 1999; Zamir et al.,

2000). The centripetal movement of these adhesions was dependent on the rearward actin

flow, and the linkage of Fn1 to actin was mediated by integrin $\alpha5\beta1$ and tensin (Pankov et al.,

2000; Zamir et al., 1999; Zamir et al., 2000). Our TIRF microscopy experiments are consistent

with these studies and show that integrin $\alpha5\beta1$ co-localizes with the regions of higher Fn1

intensity in fibrillar and non-fibrillar adhesions, and that $\alpha5\beta1^+$ focal and fibrillar adhesions are

beaded. Taken together, our studies suggest that Fn1 fibrils arise from small mobile

nanodomains containing Fn1[+] and integrin $\alpha5\beta1^+$ that move toward the cell's center. This

centripetal translocation of Fn1 nanodomains is coordinated with their organization into linear

arrays, which become longer and longer as more nanodomains are added.

The number of Fn1 localizations in nanodomains is independent of the antibody type or

amount used for staining, indicating that we are using saturating amounts of antibodies.

Together with the preservation of the nanodomain architecture upon the treatment with DOC,

our studies indicate that the non-uniform, beaded architecture is a salient feature of mature

Fn1 fibrils. Two pieces of evidence suggest that Fn1 nanodomains in fibrils are contiguous: 1)

the preservation of the linear organization and the nanoarchitecture of Fn1 fibrils after the

treatment of cells with DOC which dissolves cell membranes, and 2) the presence of fibrous

material between immunogold densities in electron micrographs (Chen et al., 1997; Dzamba

and Peters, 1991). The sparsity of Fn1 localizations between Fn1 nanodomains in fibrils

indicates that molecules other than or in addition to Fn1 participate in the linking of Fn1

nanodomains into strings.

FUD peptide specifically binds to the N-terminal assembly domain of Fn1 (Maurer et al., 2015;

Maurer et al., 2010) and acts as a competitive inhibitor of Fn1-Fn1 interactions (Ma et al.,

2015; Tomasini-Johansson et al., 2001). In the absence of FUD, individual fibrils in an

established matrix are stable and can be tracked for over 16 hours (data not shown). When

FUD is added to cells, it specifically co-localizes with Fn1 fibrils and dismantles the mature Fn1

ECM (Filla et al., 2017; Tomasini-Johansson et al., 2001), suggesting that the linear

arrangement of Fn1 nanodomains in the fibrillar ECM is maintained through dynamic

interactions mediated at least in part by the Fn1 N-terminal assembly domain. Our live imaging

experiments demonstrated that in addition to dismantling pre-existing fibrils, FUD effectively

blocks their de-novo formation. STORM showed that FUD does not affect the formation of Fn1

nanodomains, instead, it blocks the organization of Fn1 nanodomains into linear arrays.

Together, these data suggest that FUD may block the dynamic interactions between the N-

terminal Fn1 assembly domain and the factor(s) linking Fn1 nanodomains into fibrils.

The beaded architecture of Fn1 ECM has important implications for the mechanisms of ECM

formation, remodeling and signal transduction. The tensile strength of knotted strings is

significantly lower than that of strings with uniformly-aligned fibers (Arai et al., 1999; Saitta et

al., 1999), thus the beaded architecture of Fn1 fibrils may facilitate their rupture under strain

(Ohashi et al., 1999). The non-uniform, nanodomain architecture of Fn1 may facilitate the

accessibility of Fn1 fibrils to matrix metalloproteases. In this model, degradation of Fn1 fibrils

by metalloproteases may be accomplished by cleaving between Fn1 nanodomains facilitating

ECM remodeling. Finally, Fn1 is known to bind growth factors (Martino and Hubbell, 2010;

Saunders and Schwarzbauer, 2019; Wijelath et al., 2002), and cell adhesion to ECM is known

to orchestrate growth factor signaling (Hynes, 2009). Thus, Fn1 nanodomains could serve as

platforms for the binding and presentation of concentrated packets of growth factors to cells,

the organization of Fn1 nanodomains into closely-spaced arrays could further facilitate

clustering and signaling by growth factor receptors.

Acknowledgements

We thank Nathan Astrof for insightful discussions and careful reading of the manuscript,

Sydney Astrof for help with data entry and encouragement, Patrick Murphy for endothelial

cells, Richard Hynes for the gift of 297.1 antibody, and Tung Chan for help with setting up

Western Blotting using ProteinSimple.

Sources of Funding This work was supported by the funding from the National Heart, Lung,

and Blood Institute of the NIH R01 HL103920 and R01 HL134935 to SA, by the NIH Office of

the Director R21 OD025323-01 to SA, by the pre-doctoral fellowship F31HL151046 to BEA, by

the National Institute of General Medicine R35GM122505 to AK, by the National Institute of

Arthritis and Musculoskeletal and Skin Diseases R01 AR073236 to JES, by the Faculty Seed

Grant from the Center for Engineering MechanoBiology (CEMB), an NSF Science and

Technology Center, under grant agreement CMMI: 15-48571. Any opinions, findings, and

conclusions or recommendations expressed in this material are those of the authors and do

not necessarily reflect the views of the National Science Foundation.

Materials and Methods

389   Materials and Methods are in the Supplemental Methods Word File.

Data availability

392   Reagents generated as a part of this study are available upon request

Legends for Figures are included with Figures

Legends for Movies

Movie 1. Rotational views through the Fn1+ ECM in the cardiac jelly. Whole E9.5 embryo

was stained using rabbit monoclonal anti-Fn1 antibody and imaged using 100x objective, N.A.

1.49, with the pinhole set at 0.8 Airy units, and sampling of 40 nm per pixel in x, y. The movie

shows 3D reconstruction through 3.4 μm of tissue sampled every 0.121 μm in z. Fn1 is in

white, DAPI is in blue. Arrows point to examples of beaded Fn1 fibrils.

Movie 2. Fn1 fibrillogenesis imaged by TIRF microscopy. Fn1^{mEGFP} MEFs were transiently

transfected with mCardinal-lifeact, plated on gelatin-coated glass cover slips, and imaged 48

hours later. Filming was done every 2 min for 30 min using TIRF and 100x objective, N.A.

1.49. The first set shows Fn1-mEGFP channel. Yellow arrows point to centripetally-moving

Fn1 nanodomains that appear to be organizing into an elongating linear fibril. The second set

is an overlay between Fn1-mEGFP and mCardinal-lifeact.

Movie 3. 2% DOC dissolved cytoplasm and nucleus in under 13 min leaving Fn1 fibrils.

MEFs expressing Fn1-mEGFP were plated on glass-bottom slides and labeled with SiRActin

(magenta) to visualize F-actin and Hoechst (blue) to visualize DNA. Time lapse was recorded

every 54 sec immediately following the addition of DOC solution, pH 8.01, to live cells. The

addition of 2% DOC dissolves actin cytoskeleton and nuclei, and leaves Fn1 ECM fibrils

(green). Fn1 fibrils collapse following the dissolution of the actin cytoskeleton due to the loss of

tension.

Movie 4. 3D-rendering of STORM data. Fn1 fibril underlined in Fig. 4b1 is rotated around the

x-axis to show the arrangement of Fn1 localizations in 3D. The movie starts in x-y plane.

Yellow arrows point at Fn1 nanodomains in the fibrils. Red arrows point to the space between

the nanodomains.

Movie 5. Cells incubated with 11-IIIC, show robust fibrillogenesis. Fn1^{mEGFP} MEFs were

plated on glass in 8-well Ibidi chambers for 4 hours, Medium containing 11-IIIC control peptide

was then added and cells were filmed every 90 sec for about 15 hours, as described in

Methods. The movie begins approximately 30 min after the 11-IIIC-containing medium was

added, the time it takes to set up time-laps recording. Arrows point to cell periphery and

examples of centripetally moving Fn1 fibrils.

Movie 6. FUD interferes with linking centripetally moving Fn1+ nanodomains into fibrils.

Fn1^{mEGFP} MEFs were plated on glass in 8-well Ibidi chambers for 4 hours. Medium containing

FUD peptide was then added and cells were filmed every 3 min for about 15 hours, as

described in Methods. The movie begins approximately 30 min after the FUD-containing

medium was added, the time it takes to set up time-laps recording. Note the dismantling of pre-

existing fibrils at the beginning of the movie. Yellow and red arrows point to cell periphery.

Note the presence of centripetally moving Fn1-mEGFP "beads" and the scarcity of Fn1 fibrils

for the majority of the duration of the movie.

References

Arai, Y., Yasuda, R., Akashi, K., Harada, Y., Miyata, H., Kinosita, K., Jr., and Itoh, H. (1999).
Tying a molecular knot with optical tweezers. Nature *399*, 446-448.

Chen, Y., Zardi, L., and Peters, D.M. (1997). High-resolution cryo-scanning electron
microscopy study of the macromolecular structure of fibronectin fibrils. Scanning *19*, 349-355.

Chernousov, M.A., Faerman, A.I., Frid, M.G., Printseva, O., and Koteliansky, V.E. (1987).
Monoclonal antibody to fibronectin which inhibits extracellular matrix assembly. FEBS Lett *217*,
124-128.

Chiang, H.Y., Korshunov, V.A., Serour, A., Shi, F., and Sottile, J. (2009). Fibronectin is an
important regulator of flow-induced vascular remodeling. Arterioscler Thromb Vasc Biol *29*,
1074-1079.

Choi, C.K., Vicente-Manzanares, M., Zareno, J., Whitmore, L.A., Mogilner, A., and Horwitz,
A.R. (2008). Actin and alpha-actinin orchestrate the assembly and maturation of nascent
adhesions in a myosin II motor-independent manner. Nat Cell Biol *10*, 1039-1050.

Choi, M.G., and Hynes, R.O. (1979). Biosynthesis and processing of fibronectin in NIL.8
hamster cells. J Biol Chem *254*, 12050-12055.

Damsky, C.H., Knudsen, K.A., Bradley, D., Buck, C.A., and Horwitz, A.F. (1985). Distribution of
the cell substratum attachment (CSAT) antigen on myogenic and fibroblastic cells in culture. J
Cell Biol *100*, 1528-1539.

Dzamba, B.J., and Peters, D.M. (1991). Arrangement of cellular fibronectin in noncollagenous
fibrils in human fibroblast cultures. J Cell Sci *100 (Pt 3)*, 605-612.

Filla, M.S., Dimeo, K.D., Tong, T., and Peters, D.M. (2017). Disruption of fibronectin matrix
affects type IV collagen, fibrillin and laminin deposition into extracellular matrix of human
trabecular meshwork (HTM) cells. Exp Eye Res *165*, 7-19.

Fruh, S.M., Schoen, I., Ries, J., and Vogel, V. (2015). Molecular architecture of native
fibronectin fibrils. Nat Commun *6*, 7275.

Geiger, B., Bershadsky, A., Pankov, R., and Yamada, K.M. (2001). Transmembrane crosstalk
between the extracellular matrix--cytoskeleton crosstalk. Nature reviews Molecular cell biology
2, 793-805.

Geiger, B., and Yamada, K.M. (2011). Molecular architecture and function of matrix adhesions.
Cold Spring Harb Perspect Biol *3*.

Hynes, R.O. (2009). The extracellular matrix: not just pretty fibrils. Science *326*, 1216-1219.

Jimenez, A., Friedl, K., and Leterrier, C. (2020). About samples, giving examples: Optimized
Single Molecule Localization Microscopy. Methods *174*, 100-114.

Lu, J., Doyle, A.D., Shinsato, Y., Wang, S., Bodendorfer, M.A., Zheng, M., and Yamada, K.M.
(2020). Basement Membrane Regulates Fibronectin Organization Using Sliding Focal
Adhesions Driven by a Contractile Winch. Dev Cell *52*, 631-646 e634.

Ma, W., Ma, H., and Mosher, D.F. (2015). On-Off Kinetics of Engagement of FNI Modules of
Soluble Fibronectin by beta-Strand Addition. PLoS One *10*, e0124941.

Martino, M.M., and Hubbell, J.A. (2010). The 12th-14th type III repeats of fibronectin function
as a highly promiscuous growth factor-binding domain. FASEB J *24*, 4711-4721.

Maurer, L.M., Ma, W., and Mosher, D.F. (2015). Dynamic structure of plasma fibronectin. Crit
Rev Biochem Mol Biol *51*, 213-227.

Maurer, L.M., Tomasini-Johansson, B.R., Ma, W., Annis, D.S., Eickstaedt, N.L., Ensenberger,
M.G., Satyshur, K.A., and Mosher, D.F. (2010). Extended binding site on fibronectin for the
functional upstream domain of protein F1 of Streptococcus pyogenes. J Biol Chem *285*,
41087-41099.

McKeown-Longo, P.J., and Mosher, D.F. (1983). Binding of plasma fibronectin to cell layers of
human skin fibroblasts. J Cell Biol *97*, 466-472.

Morla, A., Zhang, Z., and Ruoslahti, E. (1994). Superfibronectin is a functionally distinct form of
fibronectin. Nature *367*, 193-196.

Ohashi, T., Kiehart, D.P., and Erickson, H.P. (1999). Dynamics and elasticity of the fibronectin
matrix in living cell culture visualized by fibronectin-green fluorescent protein. Proc Natl Acad
Sci U S A *96*, 2153-2158.

Pankov, R., Cukierman, E., Katz, B.Z., Matsumoto, K., Lin, D.C., Lin, S., Hahn, C., and
Yamada, K.M. (2000). Integrin dynamics and matrix assembly: tensin-dependent translocation
of alpha(5)beta(1) integrins promotes early fibronectin fibrillogenesis. J Cell Biol *148*, 1075-
1090.

Peters, J.H., and Hynes, R.O. (1996). Fibronectin isoform distribution in the mouse. I. The
alternatively spliced EIIIB, EIIIA, and V segments show widespread codistribution in the
developing mouse embryo. Cell Adhes Commun *4*, 103-125.

Rickelt, S., and Hynes, R.O. (2018). Antibodies and methods for immunohistochemistry of
extracellular matrix proteins. Matrix Biol *71-72*, 10-27.

Rozario, T., Dzamba, B., Weber, G.F., Davidson, L.A., and DeSimone, D.W. (2009). The
physical state of fibronectin matrix differentially regulates morphogenetic movements in vivo.
Dev Biol *327*, 386-398.

Saitta, A.M., Soper, P.D., Wasserman, E., and Klein, M.L. (1999). Influence of a knot on the
strength of a polymer strand. Nature *399*, 46-48.

Saunders, J.T., and Schwarzbauer, J.E. (2019). Fibronectin matrix as a scaffold for
procollagen proteinase binding and collagen processing. Mol Biol Cell *30*, 2218-2226.

Schwarzbauer, J.E. (1991). Identification of the fibronectin sequences required for assembly of
a fibrillar matrix. J Cell Biol *113*, 1463-1473.

Schwarzbauer, J.E., and DeSimone, D.W. (2011). Fibronectins, their fibrillogenesis, and in vivo
functions. Cold Spring Harbor perspectives in biology *3*.

Sechler, J.L., Rao, H., Cumiskey, A.M., Vega-Colon, I., Smith, M.S., Murata, T., and
Schwarzbauer, J.E. (2001). A novel fibronectin binding site required for fibronectin fibril growth
during matrix assembly. J Cell Biol *154*, 1081-1088.

Sechler, J.L., Takada, Y., and Schwarzbauer, J.E. (1996). Altered rate of fibronectin matrix
assembly by deletion of the first type III repeats. J Cell Biol *134*, 573-583.

Singh, P., Carraher, C., and Schwarzbauer, J.E. (2010). Assembly of fibronectin extracellular
matrix. Annu Rev Cell Dev Biol *26*, 397-419.

Singh, P., and Schwarzbauer, J.E. (2014). Fibronectin matrix assembly is essential for cell
condensation during chondrogenesis. J Cell Sci *127*, 4420-4428.

Skorstengaard, K., Jensen, M.S., Sahl, P., Petersen, T.E., and Magnusson, S. (1986).
Complete primary structure of bovine plasma fibronectin. Eur J Biochem *161*, 441-453.

Smith, M.L., Gourdon, D., Little, W.C., Kubow, K.E., Eguiluz, R.A., Luna-Morris, S., and Vogel,
V. (2007). Force-induced unfolding of fibronectin in the extracellular matrix of living cells. PLoS
Biol *5*, e268.

Sottile, J., and Chandler, J. (2005). Fibronectin matrix turnover occurs through a caveolin-1-
dependent process. Mol Biol Cell *16*, 757-768.

Tomasini-Johansson, B.R., Kaufman, N.R., Ensenberger, M.G., Ozeri, V., Hanski, E., and
Mosher, D.F. (2001). A 49-residue peptide from adhesin F1 of Streptococcus pyogenes inhibits
fibronectin matrix assembly. J Biol Chem *276*, 23430-23439.

Tsien, R.Y. (1998). The green fluorescent protein. Annual review of biochemistry *67*, 509-544.

Vega, M.E., Kastberger, B., Wehrle-Haller, B., and Schwarzbauer, J.E. (2020). Stimulation of
Fibronectin Matrix Assembly by Lysine Acetylation. Cells *9*.

Wierzbicka-Patynowski, I., Mao, Y., and Schwarzbauer, J.E. (2004). Analysis of fibronectin
matrix assembly. Current protocols in cell biology / editorial board, Juan S Bonifacino [et al]
Chapter 10, Unit 10 12.

Wijelath, E.S., Murray, J., Rahman, S., Patel, Y., Ishida, A., Strand, K., Aziz, S., Cardona, C.,
Hammond, W.P., Savidge, G.F.*, et al.* (2002). Novel Vascular Endothelial Growth Factor
Binding Domains of Fibronectin Enhance Vascular Endothelial Growth Factor Biological
Activity. Circulation research *91*, 25-31.

Zamir, E., Katz, B.Z., Aota, S., Yamada, K.M., Geiger, B., and Kam, Z. (1999). Molecular
diversity of cell-matrix adhesions. J Cell Sci *112 (Pt 11)*, 1655-1669.

Zamir, E., Katz, M., Posen, Y., Erez, N., Yamada, K.M., Katz, B.Z., Lin, S., Lin, D.C.,
Bershadsky, A., Kam, Z.*, et al.* (2000). Dynamics and segregation of cell-matrix adhesions in
cultured fibroblasts. Nat Cell Biol *2*, 191-196.

Zhang, F., Saha, S., and Kashina, A. (2012). Arginylation-dependent regulation of a proteolytic
product of talin is essential for cell-cell adhesion. J Cell Biol *197*, 819-836.

Zhang, Q., Checovich, W.J., Peters, D.M., Albrecht, R.M., and Mosher, D.F. (1994).
Modulation of cell surface fibronectin assembly sites by lysophosphatidic acid. J Cell Biol *127*,
1447-1459.

Zhang, Q., Magnusson, M.K., and Mosher, D.F. (1997). Lysophosphatidic acid and
microtubule-destabilizing agents stimulate fibronectin matrix assembly through Rho-dependent
actin stress fiber formation and cell contraction. Mol Biol Cell *8*, 1415-1425.

Zhong, C., Chrzanowska-Wodnicka, M., Brown, J., Shaub, A., Belkin, A.M., and Burridge, K.
(1998). Rho-mediated contractility exposes a cryptic site in fibronectin and induces fibronectin
matrix assembly. J Cell Biol *141*, 539-551.

Zhou, X., Rowe, R.G., Hiraoka, N., George, J.P., Wirtz, D., Mosher, D.F., Virtanen, I.,
Chernousov, M.A., and Weiss, S.J. (2008). Fibronectin fibrillogenesis regulates three-
dimensional neovessel formation. Genes Dev *22*, 1231-1243.
561